Williams Andrew M, Theophanous Christos, Muir Kelly W, Rosdahl Jullia A, Woolson Sandra, Olsen Maren, Bosworth Hayden B, Hung Anna
From the Department of Ophthalmology (A.M.W., C.T., K.W.M., J.A.R., H.B.B.), Duke University School of Medicine, Durham, North Carolina, USA; Department of Ophthalmology (A.M.W.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
From the Department of Ophthalmology (A.M.W., C.T., K.W.M., J.A.R., H.B.B.), Duke University School of Medicine, Durham, North Carolina, USA.
Am J Ophthalmol. 2022 Dec;244:216-227. doi: 10.1016/j.ajo.2022.08.011. Epub 2022 Aug 21.
To assess the within-trial cost-effectiveness of a behavioral intervention to improve glaucoma medication adherence.
Prospective cost-effectiveness analysis of randomized, controlled trial data.
The study setting was a Veterans Affairs (VA) eye clinic. The patient population comprised veterans with medically treated glaucoma and self-reported poor adherence. Participants were randomized to a personalized educational session with a reminder bottle to promote medication adherence or to a control session on general eye health. Costs were assessed from the perspective of the VA payor at 6 months using the VA Managerial Cost Accounting System. Probabilistic sensitivity analyses were conducted using bootstrapped samples. The main outcome measures were the proportion of participants attaining ≥80% adherence as measured by electronic monitor, total intervention and medical resource costs, and incremental cost-effectiveness ratios comparing intervention to control at 6 months.
Of 200 randomized participants, 95 of 100 assigned to the intervention and 97 of 100 assigned to the control had adherence outcomes at 6 months, and the proportion of adherent patients was higher in the intervention group compared to control (0.78 vs 0.40, P < .0001). All participants had costs at 6 months. The total cost at 6 months was $1,149,600 in the intervention group (n = 100) compared to $1,298,700 in the control group (n = 100). Thus, in a hypothetical cohort of 100 patients, the intervention was associated with cost savings (-$149,100) and resulted in 38 additional patients achieving medication adherence.
An adherence-enhancing behavioral intervention was effective and cost saving at 6 months.
评估一种行为干预措施在提高青光眼药物治疗依从性方面的试验内成本效益。
对随机对照试验数据进行前瞻性成本效益分析。
研究地点为一家退伍军人事务部(VA)眼科诊所。患者群体为接受药物治疗的青光眼退伍军人且自我报告依从性差。参与者被随机分为接受个性化教育课程并配有提醒瓶以促进药物依从性的组,或接受关于一般眼部健康的对照组。使用VA管理成本核算系统从VA付款人的角度在6个月时评估成本。使用自抽样样本进行概率敏感性分析。主要结局指标包括通过电子监测器测量的达到≥80%依从性的参与者比例、总干预和医疗资源成本,以及比较6个月时干预组与对照组的增量成本效益比。
在200名随机参与者中,分配到干预组的100人中有95人、分配到对照组的100人中有97人在6个月时有依从性结果,干预组中依从患者的比例高于对照组(0.78对0.40,P <.0001)。所有参与者在6个月时都有成本。干预组(n = 100)6个月时的总成本为1,149,600美元,而对照组(n = 100)为1,298,700美元。因此,在一个假设的100名患者队列中,干预措施可节省成本(-149,100美元),并使另外38名患者实现药物依从性。
一种增强依从性的行为干预措施在6个月时有效且节省成本。